BCHE and Alzheimer disease: Cholinesterase inhibitors, including donepezil and rivastigmine, show modest time-limited benefits for individuals with Alzheimer’s disease (AD) but are more likely to be effective for the treatment of attentional dysfunction (Eagger et al., 1992; Sahakian et al., 1993).